Lachman Vol2 Parenteral PDF

cover
cover n e x t pa ge >
Start of Citation[PU]Marcel Dekker, Inc.[/PU][DP]1992[/DP]End of Citation
title : Pharmaceutical Dosage Forms. Vol. 2: Parenteral Medications

author : Avis, Kenneth E.
publisher :
isbn10 | asin : 0824787714
print isbn13 : 9780824787714
ebook isbn13 : 9780585267005
language :
subject
publication date :
lcc :
ddc :
subject :
cover n e x t pa ge >
file:///D|/HoaCND/vol%202/files/cover.html1/12/2010 6:42:37 PM
page_i
< pr e viou s pa ge page_i n e x t pa ge >

Page i
Pharmaceutical Dosage Forms:

Parenteral Medications Volume 2
Second Edition, Revised and Expanded
Edited by
Kenneth E. Avis
The University of Tennessee
Memphis, Tennessee
Herbert A. Lieberman
H.H. Lieberman Associates, Inc.
Consultant Services
Livingston, New Jersey
Leon Lachman
Lachman Consultant Services
Westbury, New York
< pr e viou s pa ge page_i n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_i.html1/12/2010 6:42:38 PM
page_ii
< pr e viou s pa ge page_ii n e x t pa ge >

Page ii
Library of Congress CataloginginPublication Data
Pharmaceutical dosage forms, parenteral medications / edited by

Kenneth E. Avis, Herbert A. Lieberman, and Leon Lachman. -- 2nd ed.,
rev. and expanded.
p. cm.
Includes bibliographical references and index.
ISBN 0-8247-8576-2 (v. 1 : alk. paper)
1. Parenteral solutions. 2. Pharmaceutical technology. I. Avis,
Kenneth E. II. Lieberman, Herbert A.
III. Lachman, Leon.
[DNLM: 1. Infusions, Parenteral. 2. Technology, Pharmaceutical.
WB 354 P536]
RS201.P37P48 1992
615'. 19--dc20
DNLM/DLC
for Library of Congress 91 -38063
CIP
This book is printed on acid-free paper.
Copyright © 1992 by MARCEL DEKKER, INC. All Rights Reserved
Neither this book nor any part may be reproduced or transmitted in any form
or by any means, electronic or mechanical, including photocopying, microfilming,
and recording, or by any information storage and retrieval system,
without permission in writing from the publisher.
MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016
Current printing (last digit):

10 9 8 7 6 5 4 3
PRINTED IN THE UNITED STATES OF AMERICA

< pr e viou s pa ge page_ii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_ii.html1/12/2010 6:42:38 PM
page_iii
< pr e viou s pa ge page_iii n e x t pa ge >

Page iii
Preface
Volume 2 of the first edition of our two-volume treatise on parenterals was published in 1986. In keeping with the
editors' philosophy to update and adequately cover new subject matter, this second volume is now being published as
part of a three-volume second edition of the series.
Volume 1 in the second edition is devoted to parenteral drug history, administration, routes, precautions, problems,
biopharmaceutics, preformulations, small and large volume parenteral formulations, peptide and protein injectables,
sterile diagnostics, different types of parenteral primary packages and closures, and, finally, parenteral products in
hospital and home care. Volume 2 describes processing small and large volume parenterals, freeze drying, the design of
a parenteral and a biopharmaceutical facility, personnel practices and training, environmental control elements in
manufacturing, industrial sterilization, as well as an enlightening coverage of the therapeutics, types of drugs, and
formulation principles for ophthalmic preparations. The final and third volume in this series covers quality assurance,
records and reports, particulate matter, validations, federal regulations, the audit process, regulatory considerations and
other aspects of medical devices, including design, manufacture, and quality assurance.
The editors have consistently guided the contributors to cover each subject with the intent of teaching at the level of the
undergraduate, as well as the graduate student in the pharmaceutical sciences. To accomplish this goal, the writers had
to assume the readers to have little knowledge of the subject matter and then build upon the more basic concepts
presented to reach the more learned and graduate level readers. Further, the materials presented in this series are
intended to benefit the technical readers with the specific information required to guide professionals practicing
industrial or pharmaceutical pharmacy, to assist personnel involved in the design and manufacture of sterile products, as
well as to instruct lawyers and legislators concerned with all types of sterile products.
< pr e viou s pa ge page_iii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_iii.html1/12/2010 6:42:38 PM
page_iv
< pr e viou s pa ge page_iv n e x t pa ge >

Page iv
All of the first-edition chapters included in this volume have been updated, and additional topics are included in each
revised chapter to more fully cover the changes in the subject matter since the publication of the first edition. Also, new
chapters have been added.
Chapter 1 on the processing of small volume parenterals, has been expanded to include several types of biologic
products, including biotechnology-based preparations such as vaccines and monoclonal antibodies. There is a discussion
on preparing liposomal products, as well as a brief description concerning the manufacture of ophthalmic dosage forms.
The use of form, fill, and seal equipment for small volume parenterals is described in detail with several diagrams and
illustrations included to help provide additional clarity to this subject. Many of the tables have been revised and the list
of references updated. The chapter is designed to provide all the necessary details for setting up and running a state-of-
the-art small volume parenteral facility.
In Chapter 2, the manufacturing processes describing large volume parenterals, has been considerably expanded
compared with the presentation given in the first edition. Recent developments in the technology of parenteral fluid
processing, the latest regulatory requirements, packaging (including currently employed materials), filling, sterilization,
and filtration operations, as all of them pertain to large volume parenterals, are fully covered. In addition, the various
factors involved in manufacturing large volume parenterals are reinforced by offering practical examples of situations
and processes, both for improving production and quality assurance and control purposes.
Chapter 3, "Freeze Drying: Principles and Practice," a new chapter in this edition, presents an overview of the scientific
and engineering principles of freeze drying as it is relevant to the formulation and manufacture of freeze-dried
parenteral products. Methodology for the characterization of freezing behavior is presented from the standpoint of
identifying the maximum allowable product temperature during primary drying, that is, either a collapse temperature
(amorphous solute) or a eutectic temperature (crystalline solute). Temperature and pressure measurement methods used
in freeze drying are reviewed, followed by a discussion of process monitoring strategies. General equipment and
considerations involved in designing a freeze drying system are discussed.
Chapter 4 updates the various design considerations required for a parenteral production facility. Specific reference has
been included to small specialized batch operations where localized and self-contained sterile enclosures may be
applicable, as for example, in the manufacture of lyophilized products. A discussion of clean-in-place (CIP) and
sterilizein-place (SIP) systems has been added. The HEPA filters topic has been updated and expanded in accordance
with the current federal and Institute of Environmental Science standards. Laminar flow rooms with an illustration,
separate gowning and degowning areas, various safety, environmental, hazardous material control, energy conservation,
and building code issues have been reviewed and revised to reflect current pharmaceutical practices.
Chapter 5, which is new, describes the design of biopharmaceutical manufacturing facilities, concentrating on the
physical layout, with particular consideration for the planning and regulatory issues that need to be addressed.
Government regulatory maters, NIH guidelines, and FDA Good Manufacturing Practices as they pertain to the
manufacture of biopharmaceutical products are discussed. The role of validation in the
< pr e viou s pa ge page_iv n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_iv.html1/12/2010 6:42:38 PM
page_v
< pr e viou s pa ge page_v n e x t pa ge >

Page v
planning process is presented along with a description of the design of the equipment outlay. This chapter highlights the
differences in planning for a biopharmaceutical manufacturing facility as compared with the design of aseptic facilities
for parenteral products.
No text concerned with the manufacture of sterile products would be complete without a description of "Personnel: The
Key Factor in Clean Room Operations," Chapter 6 of this text. The production personnel and the garments they wear
when processing sterile preparations can play a significant role in the risk of contaminating these products in the
manufacturing operations. To minimize this source of contamination, the chapter has provided a description of the
concepts of barrier technology and a lengthy discussion on the design of clean room uniforms, fabrics currently
prescribed, tests used to evaluate fabrics, and the effects of laundering on garment permeability. Several types of face
coverings worn by clean room operators are also described. Hand protection from microbial contamination and various
hand washing techniques utilized by employees working in aseptic areas are discussed. Overall contents of a training
program for clean room operators, as well as a section on management philosophy and their commitment to regulatory
compliance, are included in this chapter.
Chapter 7, "Environmental Control in Parenteral Drug Manufacturing," has been rewritten to include more details
regarding environmental monitoring, validation of airborne and surface contamination, and the implementation of a
routine monitoring program. This chapter discusses the hardware presently recommended for clean room construction
and air filtration and also includes current regulatory requirements on these subjects. New topics included in this chapter
are cleaning, disinfection, and personnel cleanliness requirements needed to achieve adequate environmental conditions
for an aseptic manufacturing facility.
"Industrial Sterilization: A Review of Current Principles and Practices," Chapter 8, describes many of the recent
advances that have been introduced in the health care industry. New concepts and principles relating to sterility
assurance techniques and procedures have been added in this edition. Among the new subjects described are alternatives
to ethylene oxide sterilization (e.g., vapor phase hydrogen peroxide, chlorine dioxide, and peracetic acid), parametric
release, chemical sterility indicators, and continuous sterilizers. Coverage of all the key areas of sterilization technology
have been expanded and include radiation, installation/performance qualification and validation, as well as a discussion
concerning the health effects of ethylene oxide as a sterilant.
Since ophthalmic preparations must be sterile, although not pyrogenfree, the editors have included in this series a new
chapter, Chapter 9, "Development of Ophthalmic Formulations." Although the dosage form is not a parenteral, the
techniques required for sterile formulation development are the same, and in other texts on sterile products, this topic is
not adequately covered. In this chapter, topical ophthalmic products are discussed, andunlike many other pharmacy
textsthe emphasis is on the development of intraocular preparations, particularly irrigating solutions. Included in this
chapter is a review of the anatomy of the eye and the pharmacologic/therapeutic categories of drugs used in
ophthalmology practice. It also includes a flow chart with model formulations for the development of ophthalmic
preparations. Manufacturing procedures for the preparation and packaging of ophthalmic products are briefly described.
< pr e viou s pa ge page_v n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_v.html1/12/2010 6:42:39 PM
page_vi
< pr e viou s pa ge page_vi n e x t pa ge >

Page vi
The multiauthor approach taken in this volume, as well as the others in the series, provides the editors and readers with
contributors who are scholars knowledgeable as well as experienced in the subject matter of their chapters. No one
author can offer the detailed and learned treatise required to adequately cover such a variety of subjects included in this
volume. The experts chosen in particular areas offer comprehensive knowledge at a level that will satisfy the
requirements of both the novice and the highly experienced reader.
The contributing authors have worked hard to provide our readers with information needed to help them solve problems
in manufacturing all types of sterile parenteral, biologic, and ophthalmic products. We are extremely grateful for the
time and effort each has given to prepare a chapter despite a busy work schedule. We hope that the extensive coverage
of the subject matter in this book will facilitate the reader's tasks, as well as elevate the present technology practiced in
developing and manufacturing parenteral, biologic, and ophthalmic products.
KENNETH E. AVIS
HERBERT A. LIEBERMAN
LEON LACHMAN
< pr e viou s pa ge page_vi n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_vi.html1/12/2010 6:42:39 PM
page_vii
< pr e viou s pa ge page_vii n e x t pa ge >

Page vii
Contents
Preface iii
Contributors ix
Contents of Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1 and 3 xi
Contents of Pharmaceutical Dosage Forms: Tablets, Volumes 1-3 xiii
Contents of Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1 and 2 xv
1. The Processing of Small Volume Parenterals and Related Sterile Products 1

Richard J. Harwood, Joel Benton Portnoff, And Edward William Sunbery
2. Factors Involved in Manufacturing Large Volume Parenterals 93

Michael J. Groves, Karen L. Malik, And Nicholas J. Kartinos
3. Freeze Drying: Principles and Practice 163

Steven L. Nail And Larry A. Gatlin
4. Design Considerations for a Parenteral Production Facility 235

A. Michael Keller And Gary L. Hoffman
5. Biopharmaceutical Manufacturing Facility Design 317

Robert Del Ciello
6. Personnel: The Key Factor in Clean Room Operations 367

Cecelia J. Luna
7. Environmental Control in Parenteral Drug 411

Manufacturing
Franco Devecchi
< pr e viou s pa ge page_vii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_vii.html1/12/2010 6:42:39 PM
page_viii
< pr e viou s pa ge page_viii n e x t pa ge >

Page viii
8. Industrial Sterilization: A Review of Current Principles and Practices 473

Frank J. Marino
9. Development of Ophthalmic Formulations 541

Krishna M. Bapatla And 0. J. Lorenzetti
Index 583
< pr e viou s pa ge page_viii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_viii.html1/12/2010 6:42:39 PM
page_ix
< pr e viou s pa ge page_ix n e x t pa ge >

Page ix
Contributors
Krishna M. Bapatla, Ph.D. Associate Director, Project Management, Alcon Laboratories, Inc., Fort Worth, Texas
Robert Del Ciello, P.E. Director, Pharmaceutical and Biotechnology Operations, Quasar Engineering, Inc., Princeton,
New Jersey
Franco DeVecchi Chairman of the Board, Veco International, Inc., Farmington Hills, Michigan
Larry A. Gatlin, Ph.D. Section Head, Parenteral and Enteral Liquid Product Development, Pharmaceutical Research and
Development, Glaxo Research Institute, Research Triangle Park, North Carolina
Michael J. Groves, Ph.D. Director, Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at
Chicago, Chicago, Illinois
Richard J. Harwood, Ph.D, Director, Technical Planning, Strategic Management Operations, Bristol-Myers Squibb,
Princeton, New Jersey
Gary L. Hoffman Merck Pharmaceutical Manufacturing Division, West Point, Pennsylvania
Nicholas J. Kartinos, Ph.D. Consultant, Chicago, Illinois
A. Michael Keller, P.E. Project Manager, Budlong & Associates, Agoura Hills, California
O. J. Lorenzetti, Ph.D. Senior Director, Therapeutic Research, Research and Development, Alcon Laboratories, Inc.,
Fort Worth, Texas
Cecelia J. Luna Validation Project Manager, Validation Services, United Engineers & Constructors, Philadelphia,
Pennsylvania
< pr e viou s pa ge page_ix n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_ix.html1/12/2010 6:42:40 PM
page_x
< pr e viou s pa ge page_x n e x t pa ge >

Page x
Karen L. Malik Baxter Healthcare Laboratories, Inc., Round Lake, Illinois
Frank J. Marino, M.S. Corporate Consultant, Microbiology, Corporate Quality Assurance, Abbott Laboratories, North
Chicago, Illinois
Steven L. Nail, Ph.D. Associate Professor, Industrial and Physical Pharmacy, Purdue University, West Lafayette,
Indiana
Joel Benton Portnoff Executive Director of Development, Analytical and Pharmaceutical Research and Development,
The Liposome Company, Inc., Princeton, New Jersey
Edward William Sunbery, RPh. Manager, Technical Services, WarnerLambert Company, Inc., Lititz, Pennsylvania
< pr e viou s pa ge page_x n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_x.html1/12/2010 6:42:40 PM
page_xi
< pr e viou s pa ge page_xi n e x t pa ge >

Page xi
Contents of Pharmaceutical Dosage Forms:

Parenteral Medications, Second Edition, Revised and Expanded, Volumes 1 and 3
Volume 1
1. The Parenteral Dosage Form and Its Historical Development, Kenneth E. Avis
2. Parenteral Drug Administration: Routes, Precautions, Problems, Complications, and Drug Delivery Systems, Richard
J. Duma, Michael J. Akers, and Salvatore J. Turco
3. Biopharmaceutics of Injectable Medications, Sol Motola
4. Preformulation Research of Parenteral Medications, Sol Motola and Shreeram N. Agharkar
5. Formulation of Small Volume Parenterals, Patrick P. DeLuca and James C. Boylan
6. Formulation of Large Volume Parenterals, Levit J. Demorest and Jeffrey G. Hamilton
7. Parenteral Products of Peptides and Proteins, Yu-Chang John Wang
8. Sterile Diagnostics, Leif E. Olsen
9. Glass Containers for Parenterals, R. Paul Abendroth and Robert N. Clark
10. Use of Plastics for Parenteral Packaging, John M. Anes, Robert S. Nase, and Charles H. White
11. Elastomeric Closures for Parenterals, Edward J. Smith and Robert J. Nash
12. Parenteral Products in Hospital and Home Care Pharmacy Practice, John W. Levchuk
< pr e viou s pa ge page_xi n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xi.html1/12/2010 6:42:40 PM
page_xii
< pr e viou s pa ge page_xii n e x t pa ge >

Page xii
Volume 3
1. Quality Assurance
Samir A. Hanna
2. Records and Reports

David C. Fry
3. Particulate Matter
Patrick P. DeLuca and Julius Z. Knapp
4. Validation of Sterilization Processes and Sterile Products

James Agalloco and James Akers
5. Federal Regulation of Parenterals

Terry E. Munson, Jonas L. Bassen, and Bernard T. Loftus
6. Systematic Audits of Parenteral Good Manufacturing Practices

Ronald F. Tetzlaff
7. Medical Devices: Design, Manufacture, and Quality Control

David H. Wayt
8. Quality Assurance for Medical Devices

Carl W. Bruch
9. Regulatory and GMP Considerations for Medical Devices

Larry R. Pilot
< pr e viou s pa ge page_xii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xii.html1/12/2010 6:42:40 PM
page_xiii
< pr e viou s pa ge page_xiii n e x t pa ge >

Page xiii

Tablets, Second Edition, Revised and Expanded, Volumes 1-3
edited by Herbert A. Lieberman, Leon Lachman, and Joseph B. Schwartz
Volume 1
1. Preformulation Testing, Deodatt A. Wadke, Abu T. M. Serajuddin, and Harold Jacobson
2. Tablet Formulation and Design, George J. Baley, Vincent E. McCurdy, Garnet E. Peck, and Gilbert S. Banker
3. Compressed Tablets by Wet Granulation, Fred J. Bandelin
4. Compressed Tablets by Direct Compression, Ralph F. Shangraw
5. Compression-Coated and Layer Tablets, William C. Gunsel and Robert G. Dusel
6. Effervescent Tablets, Raymond Mohrle
7. Special Tablets, James W. Conine and Michael J. Pikal
8. Chewable Tablets, Robert W. Mendes, Aloysius O. Anaebonam, and Jahan B. Daruwala
9. Medicated Lozenges, David Peters

< pr e viou s pa ge page_xiii n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xiii.html1/12/2010 6:42:41 PM
page_xiv
< pr e viou s pa ge page_xiv n e x t pa ge >

Page xiv
Volume 2
1. Mixing,
Russell J. Lantz, Jr. and Joseph B. Schwartz
2. Drying,
Kurt G. Van Scoik, Michael A. Zoglio, and Jens T. Carstensen
3. Size Reduction,
Russell J. Lantz, Jr.
4. Compression,
Eugene L. Parrott
5. Granulation and Tablet Characteristics,

Roger E. Gordon, Dale E. Fonner, Neil R. Anderson, and Gilbert S. Banker
6. Bioavailability in Tablet Technology,

Salomon A. Stavchanskv, James W. McGinity, and Alfred Martin
7. Pharmaceutical Tablet Compression Tooling,

Glen Ebey and George F. Loeffler
Volume 3
1. Principles of Improved Tablet Production System Design,

Garnet E. Peck, Neil R. Anderson, and Gilbert S. Banker
2. Pan Coating of Tablets and Granules,

Stuart C. Porter
3. Particle-Coating Methods,
Dale E. Wurster
4. Sustained Drug Release from Tablets and Particles through Coating,

Rong-Kun Chang and Joseph R. Robinson
5. Pharmaceutical Pilot Plant,

Charles I. Jarowski
6. Tablet Production,
Robert Connelly, Frank Berstler, and David Coffin-Beach
7. Stability/Kinetics,
Samir A. Hanna
8. Quality Assurance,
Samir A. Hanna
< pr e viou s pa ge page_xiv n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xiv.html1/12/2010 6:42:41 PM
page_xv
< pr e viou s pa ge page_xv n e x t pa ge >

Page xv

Disperse Systems, Volumes 1 and 2
edited by Herbert A. Lieberman, Martin M. Rieger, and Gilbert S. Banker
Volume 1
1. Introduction,
Norman Weiner
2. Theory of Suspensions,
Michael J. Falkowicz
3. Theory of Emulsions,
Stig E. Friberg, Lisa B. Goldsmith, and Martha L. Hilton
4. Theory of Colloids,
John Vanderhoff and Mohamed S. El-Aasser
5. Pharmaceutical Suspensions,
Robert A. Nash
6. Pharmaceutical Emulsions,
Bernard Idson
7. Specialized Pharmaceutical Emulsions,

Morton Rosoff
8. Surfactants,
Martin M. Rieger
9. Rheology of Dispersed Systems,

Donald E. Deem
10. Experimental Design, Modeling, and Optimization Strategies for Product and Process Development,
Robert M. Franz, Jeffrey E. Browne, and Allen R. Lewis
Volume 2
1. A Practical Guide to Equipment Selection and Operating Techniques

Roy R. Scott
2. Preservation of Dispersed Systems

Harun Takruri and Claude B. Anger
< pr e viou s pa ge page_xv n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xv.html1/12/2010 6:42:41 PM
page_xvi
< pr e viou s pa ge page_xvi n e x t pa ge >

Page xvi
3. Bioavailability of Disperse Dosage Forms

Ronald D. Schoenwald and Douglas R. Flanagan
4. Viscosity-Imparting Agents in Disperse Systems

Joel L. Zatz, Joseph J. Berry, and Daniel A. Alderman
5. Antacids and Clay Products

Richard J. Harwood, Joseph R. Luber, and Edward W. Sunbery
6. Oral Aqueous Suspensions

Clyde M. Ofner III, Roger L. Schnaare, and Joseph B. Schwartz
7. Topical Suspensions
Hridaya N. Bhargava and Daniel W. Nicolai
8. Reconstitutable Suspensions
Clyde M. Ofner III, Roger L. Schaare, and Joseph B. Schwartz
9. Emulsions and Microemulsions

Lawrence H. Block
10. Injectable Emulsions and Suspensions

Joe Bruce Boyett and Craig William Davis
11. Aerosol Suspensions and Emulsions

John J. Sciarra and Anthony J. Cutie
12. Ophthalmic Ointment Suspensions

Krishna M. Bapatla and Gerald Hecht
13. Gels
Joel L. Zatz and Gregory P. Kushla
14. Toothpastes
David Garlen
15. Suppository Development and Production Marion

Gold
16. Liposomes
Mohammad Riaz, Norman Weiner, and Frank Martin
17. Drug Regulatory Affairs

John P. Tomaszewski
18. Quality Assurance

Samir A. Hanna
< pr e viou s pa ge page_xvi n e x t pa ge >
file:///D|/HoaCND/vol%202/files/page_xvi.html1/12/2010 6:42:42 PM
page_1
< pr e viou s pa ge page_1 n e x t pa ge >

file:///D|/HoaCND/vol%202/files/page_1.html1/12/2010 6:42:42 PM
page_2

page_3

page_4

page_5

page_6

page_7

page_8

page_9

page_10

page_11

page_12

page_13

page_14

page_15

page_16

page_17

page_18

page_19

page_20

page_21

page_22

page_23

page_24

page_25

page_26

page_27

page_28

page_29

page_30

page_31

page_32

page_33

page_34

page_35

page_36

page_37

page_38

page_39

page_40

page_41

page_42

page_43

page_44

page_45

page_46

page_47

page_48

page_49

page_50

page_51

page_52

page_53

page_54

page_55

page_56

page_57

page_58

page_59

page_60

page_61

page_62

page_63

page_64

page_65

page_66

page_67

page_68

page_69

page_70

page_71

page_72

page_73

page_74

page_75

page_76

page_77

page_78

page_79

page_80

page_81

page_82

page_83

page_84

page_85

page_86

page_87

page_88

page_89

page_90

page_91

page_92

page_93

page_94

page_95

page_96

page_97

page_98

page_99

page_100

page_101

page_102

page_103

page_104

page_105

page_106

page_107

page_108

page_109

page_110

page_111

page_112

page_113

page_114

page_115

page_116

page_117

page_118

page_119

page_120

page_121

page_122

page_123

page_124

page_125

page_126

page_127

page_128

page_129

page_130

page_131

page_132

page_133

page_134

page_135

page_136

page_137

page_138

page_139

page_140

page_141

page_142

page_143

page_144

page_145

page_146

page_147

page_148

page_149

page_150

page_151

page_152

page_153

page_154

page_155

page_156

page_157

page_158

page_159

page_160

page_161

page_162

page_163

page_164

page_165

page_166

page_167

page_168

page_169

page_170

page_171

page_172

page_173

page_174

page_175

page_176

page_177

page_178

page_179

page_180

page_181

page_182

page_183

page_184

page_185

page_186

page_187

page_188

page_189

page_190

page_191

page_192

page_193

page_194

page_195

page_196

page_197

page_198

page_199

page_200

page_201

page_202

page_203

page_204

page_205

page_206

page_207

page_208

page_209

page_210

page_211

page_212

page_213

page_214

page_215

page_216

page_217

page_218

page_219

page_220

page_221

page_222

page_223

page_224

page_225

page_226

page_227

page_228

page_229

page_230

page_231

page_232

page_233

page_235

page_236

page_237

page_238

page_239

page_240

page_241

page_242

page_243

page_244

page_245

page_246

page_247

page_248

page_249

page_250

page_251

page_252

page_253

page_254

page_255

page_256

page_257

page_258

page_259

page_260

page_261

page_262

page_263

page_264

page_265

page_266

page_267

page_268

page_269

page_270

page_271

page_272

page_273

page_274

page_275

page_276

page_277

page_278

page_279

page_280

page_281

page_282

page_283

page_284

page_285

page_286

page_287

page_288

page_289

page_290

page_291

page_292

page_293

page_294

page_295

page_296

page_297

page_298

page_299

page_300

page_301

page_302

page_303

page_304

page_305

page_306

page_307

page_308

page_309

page_310

page_311

page_312

page_313

page_314

page_315

page_316

page_317

page_318

page_319

page_320

page_321

page_322

page_323

page_324

page_325

page_326

page_327

page_328

page_329

page_330

page_331

page_332

page_333

page_334

page_335

page_336

page_337

page_338

page_339

page_340

page_341

page_342

page_343

page_344

page_345

page_346

page_347

page_348

page_349

page_350

page_351

page_352

page_353

page_354

page_355

page_356

page_357

page_358

page_359

page_360

page_361

page_362

page_363

page_364

page_365

page_366

page_367

page_368

page_369

page_370

page_371

page_372

page_373

page_374

page_375

page_376

page_377

page_378

page_379

page_380

page_381

page_382

page_383

page_384

page_385

page_386

page_387

page_388

page_389

page_390

page_391

page_392

page_393

page_394

page_395

page_396

page_397

page_398

page_399

page_400

page_401

page_402

page_403

page_404

page_405

page_406

page_407

page_408

page_409

page_410

page_411

page_412

page_413

page_414

page_415

page_416

page_417

page_418

page_419

page_420

page_421

page_422

page_423

page_424

page_425

page_426

page_427

page_428

page_429

page_430

page_431

page_432

page_433

page_434

page_435

page_436

page_437

page_438

page_439

page_440

page_441

page_442

page_443

page_444

page_445

page_446

page_447

page_448

page_449

page_450

page_451

page_452

page_453

page_454

page_455

page_456

page_457

page_458

page_459

page_460

page_461

page_462

page_463

page_464

page_465

page_466

page_467

page_468

page_469

page_470

page_471

page_472

page_473

page_474

page_475

page_476

page_477

page_478

page_479

page_480

page_481

page_482

page_483

page_484

page_485

page_486

page_487

page_488

page_489

page_490

page_491

page_492

page_493

page_494

page_495

page_496

page_497

page_498

page_499

page_500

page_501

page_502

page_503

page_504

page_505

page_506

page_507

page_508

page_509

page_510

page_511

page_512

page_513

page_514

page_515

page_516

page_517

page_518

page_519

page_520

page_521

page_522

page_523

page_524

page_525

page_526

page_527

page_528

page_529

page_530

page_531

page_532

page_533

page_534

page_535

page_536

page_537

page_538

page_539

page_540

page_541

page_542

page_543

page_544

page_545

page_546

page_547

page_548

page_549

page_550

page_551

page_552

page_553

page_554

page_555

page_556

page_557

page_558

page_559

page_560

page_561

page_562

page_563

page_564

page_565

page_566

page_567

page_568

page_569

page_570

page_571

page_572

page_573

page_574

page_575

page_576

page_577

page_578

page_579

page_580

page_581

page_583

Page 583
Index
Absorption of drugs from the eye, 555-555
Adrenergic antagonists, 549
Allergenic SVP extracts, 2
Anti-inflammatory agents, 550
Antimicrobial preservatives, 550, 558-559
Antioxidants, 561, 573
Aqueous ophthalmic solution products, 64-66
Aqueous solutions, freezing of, 166-173
Aseptic techniques, 474
for packaging and sealing, 77-80
via form/fill/seal technology, 86-87, 88-89
Bacterial vaccines, 67-68
Barrier technology, applications of, for cleanroom operation, 389-391
Benzalkonium chloride, 558
Biological SVP products, 1
Biopharmaceutical manufacturing facility design, 317-366
architectural treatments, 336-341
design methodology, 321-329
construction documents, 329
design basis development, 329
design development, 329
planning, 321
file:///D|/HoaCND/vol%202/files/page_583.html (1 of 3)1/12/2010 6:45:03 PM

page_583
development of facility layout, 329-336
HVAC/environmental system design, 341-350
air handlers, 347-348
control and control devices, 348
design criteria, 342- 343
duct systems, 348
dust control, 347
filtration, 346-347
pressurization, 343-346
system classification, 349-350
temperature and relative humidity, 346
large-scale biosafety level facility requirements, 319
regulatory issues, 318-320
utility systems, 350, 365
aseptic compressed air systems, 364
biological waste treatment systems, 351-356
clean-in-place systems, 360-362, 363
clean (sterile) steam systems, 363-364
electrical service, 364
temperature control systems, 364-365
water systems, 356-360
Buffering agents, 559, 572
Cake filters, 123
Carbon steel piping, 268
Cartridge filters, 135
Center for Biologics of the Food and Drug Administration, 318
Chelating agents, 573
Chlorine compounds for sterilization, 500

page_583
Chlorobutanol, 558-559
Cleanroom operations personnel, 367-410
application of barrier technology to the cleanroom operation, 389-391
contamination, 368-370, 451-452


page_584

Page 584
microbial contamination, 370
particulate contamination, 368-370
management role in cleanroom operations, 404-409
development of a positive attitude, 408-409
management philosophy and commitment to regulatory compliance, 407
motivation of employees, 405-406
personnel characteristics, 370-374
bacterial load, 370-371
body area shedding organisms, 371-372
the carrier concept, 374
male vs. female shed rates, 373
types of microorganisms, 371
personnel factors required to control contamination, 376-386
personnel practices and procedures, 386-389
general cleanroom procedures, 387-389
practices related to gowning, 386-387
safety procedures, 388-389
selection of cleanroom personnel, 374-376
characteristics of employees, 374-376
training program for cleanroom employees, 391-404
advantages of such a program, 403-404
development of the program, 391-394
three-step program, 394-403
Cleanrooms
environmental control of, 438-451
air motion, 439-445
basis for cleanroom design, 445-451

page_584
isolation, 438-439
maintenance procedures for, 16, 17
Collapse temperatures, 172
of various compounds, 174
Contamination
by cleanroom operations personnel, 368-370, 415, 416
control of, 376-386, 451-452
factors required to control, 376-386
air as a source of contamination, 416-417
equipment and materials used in manufacturing as a source of contamination, 414
Copper piping, 268-269
Current Good Manufacturing Practices (CGMP) regulations of the Food and Drug Administration, 94
Cycloplegics, 549-550
Density, 98-99
Dental SVP products, 2
Depth filters, 122-123
advantages and disadvantages of, 126-127
Designing a parenteral production facility, 235-316
(see also Biopharmaceutical manufacturing facility design)
design concepts, 254-315
compressed air, 293-300
compressed gases, 300-302
filling suites, 254-257
heating, ventilating, and air conditioning, 274-278
laminar flow, 286-289

page_584
mechanical services, 264-274
miscellaneous controlled area details, 261-263
steam, 289-293
wall and floor treatment, 257-261
warehousing, 263-264
waste disposal, sanitation, and equipment cleaning, 312-315
water for injection, 304-312
water treatment, 302-304
facility area use planning, 239-254
area planning, 245-254
general operational assessments, 240-245
site selection, 236-239
air quality, 238
basic plant requirements, 236-237
energy, 237-238
nontechnical factors, 239
waste disposal, 238-239
water, 238
typical layout of a parenteral plant, 235, 236
Dextran, collapse temperature of, 174
Diagnostic SVP agents, 1-2
Distribution records, 5, 7
Dry eye syndrome, medications for, 550
Dry heat sterilization, 490-491
characteristics of, 488
loading considerations for, 506
D value
Environmental control in parenteral drug manufacturing, 411-472

page_584
cleaning and disinfection procedures, 452-454
cleanrooms, 438-451
air motion, 439-445
basis for cleanroom design, 445-451
isolation, 438-439
control of contamination, 414-417
air as a source of contamination, 416-417
equipment and materials used in manufacturing, 414


page_585

Page 585
personnel, 415, 416
definitions of, 474-475
environmental contamination control system design, 417-438
heating, ventilation, and air conditioning systems, 418-438
personnel contamination control, 451-452
test methods, 454-469
airborne microbial sampling in critically controlled environments, 467-468
airborne particle count test, 459-462
airflow patterns test, 463-465
airflow uniformity test, 454-455
enclosure induction leak test, 462-463
HEPA filter leak test, 458-459
humidity control test, 456
particle dispersion test, 465-466
pressurization control test, 457
recovery test, 467
surface sampling, 468-469
temperature control test, 456
Environmental records, 5, 6
Enzymatic products, 550
Equipment for freeze drying, 222-227
Ethylene oxide sterilization, 495-498
Exposure time, 479-480
Eye, absorption of drugs from, 551-555
Eye, anatomy of, 542-547

page_585
ciliary body, 546
conjunctiva, 542
cornea, 544-546
corneal endothelium and Descemet's membrane, 545
corneal epithelium, 545
corneal stroma and Bowman's membrane iris, 545-546
crystalline lens, 546-547
lacrimal system, 542-544
optic nerve and optic disc, 547
vitreous chamber, 547
Ficoll, collapse temperature of, 174
Filling areas, design concepts for, 254-257
Filtration in the LVP manufacturing process, 119-136
advantages and disadvantages of screen and depth filters, 126-127
advantages of membrane filters, 134-135
classification of filtration operations, 122-123
ideal filter criteria, 127-128
membrane support systems, 135-136
testing and validation of filters, 130-134
theories of filtration, 124-126
utilization of filters, 128-130
Formaldehyde gas for sterilization, 500-501
Fractional sterilization, 490
Freeze-dried powder formula for SVPs, preparation of, 51-61
Freeze drying, 163-233
development of freeze-dried protein formulation (case study), 227-230
freeze dry equipment, 222-227
condenser design, 225-226

page_585
general construction considerations, 226
heat transfer fluid, 225
refrigeration, 225
sterilization of freeze dryers, 226-227
vacuum integrity testing, 227
vacuum system, 223-225
freeze process, 166-185
characterization of freezing behavior, 173-185
freezing of aqueous solutions, 166-173
phase diagram of water, 166
thermal treatment, 173
primary drying process, 185-205
behavior of gases at low pressure, 187-191
heat transfer in primary drying, 191-201
mass transfer in primary drying, 201-205
sublimation of ice, 185-187
transfer operations, 187
process monitoring, 208-222
pressure measurement, 213-217
process monitoring techniques, 218-222
temperature measurement, 208-213
process overview, 164-165
secondary drying, 205-208
role of residual water in stability of freeze-dried products, 207-208
Fructose, collapse temperature of, 174
F0 value, 478-479
Garments for cleanroom operations personnel, 378-383, 386-387
Gelatin, collapse temperature of, 174

page_585
Gels, 576
Genetically engineered SVP products, 2
preparation of, 66-69
bacterial vaccines, 67-68
recombinant DNA techniques, 69
toxoids, 68-69
viral vaccines, 68
Glaucoma, agents for treatment of, 549
Glucose, collapse temperature of, 174


page_586

Page 586
Heating, ventilation, and air conditioning (HVAC) systems
airborne contamination control, 419-427
aerosol behavior, 419-421
air filtration, 421
efficiency testing, 427
evaluation of air filter system, 422-424
filter classification, 421-422
high efficiency filters, 424-426
integrity testing, 427
for biopharmaceutical manufacturing facility, 341-350
components of the HVAC system, 432-438
air distribution network, 433-436
air handling unit, 347-348, 433
control devices, 348, 436-438
monitoring and alarm devices, 438
constant airflow systems, 431-432
ventilation, 432
design concepts for, 274-286
pressure differential control, 429-431
recirculation ratio (dilution of contamination), 427-429
temperature and humidity control, 418-419
Heat transfer, 102-106
conduction, 102
convection, 103
radiation, 103
Hydrogen peroxide for low temperature sterilization, 498, 499

page_586
Industrial sterilization, 473-540
health physics, 537-538
overview of sterilization processes, 486-501
chlorine compounds, 500
dry heat, 490-491
ethylene oxide, 495-498
formaldehyde, 500-501
fractional sterilization, 490
hydrogen peroxide, 498, 499
moist heat, 487-490
peracetic acid, peracetate, 499-500
radiation, 491-495
principal definitions, 473-486
aseptic technique, 474
the D value, 475-476
environmental control, 474-475
exposure time, 479-480
the F¬ value, 478-479
packaging, 479
principles of microbial resistance, 481-482
pyrogen, 482
the Q10 value, 478
sterility, 473-474
sterilization assurance, 482-486
thermal death time and thermal chemical death time, 480-481
the Z value, 476-478
process considerations, 504-512
data analysis, 512

page_586
discipline or training requirements, 511-512
economic considerations, 506-507
regulatory considerations, 507
safety requirements, 507-511
typical sterilization loading characteristics, 504-506
process development, 519-525
calibration, 523-525
instrumentation for process control, 522-523
microbiological criteria, 519-522
parametric studies, 519
process selection, 502-504
packaging, 503-504
product consideration, 503
process specifications, 513-519
equipment, 514
facilities and space requirements, 514
installation and facilities, 515-516
processing hardware, 516-519
relationship to total operational process, 514-515
specifications, 515
technology, 513-514
validation of process and equipment, 525-537
biological validation, 525-526
process control and equipment, 526-537
Inositol, collapse temperature of, 174
Intraocular products, 550-551, 562-567
irrigating solution of, 500, 562-564, 577-578
ocular safety assessment of, 567-568

page_586
Lactose, collapse temperature of, 174
Laminar flow, design concepts for, 286-289, 292
Large volume parenterals (LVPs),
manufacture of, 93-162
batch mixing, 113-119
lipid emulsions, 118-119
simple solutions, 113-118
Specialized products, 119
cleaning process equipment and lines, 136-144
cleaning and sanitization, 139-142
compressed gases, 143-144
mixing and filling equipment, 139


page_587

Page 587
[Large volume parenterals (LVPs)]
production planning, 139
water systems, 136-139
containers and closures, 144-154
air tubes, 151
caps, 151
glass bottle handling, 147-148
glass bottle washing, 148-150
materials, 144-146
plastic containers, 151-152
rubber closures, 150-151
filling, 154
filtration, 119-136
advantages and disadvantages of screen and depth filters, 126-127
advantages of membrane filters, 134-135
classification of filtration operations, 122-123
ideal filter criteria, 127-128
membrane support systems, 135-136
testing and validation of filters, 130-134
theories of filtration, 124-126
utilization of filters, 128-130
final product testing, 157-160
particulate testing, 160
use of isolators, 157-159
fluid dynamics and heat flow, 95-106
flow of fluids in an autoclave, 101-102
heat transfer, 102-106

page_587
properties of fluids, 95-101
labeling, 155-157
new directions, 160-161
process validation, 160
raw materials, 110-113
definition, 110-111
distribution and inventory control, 113
qualification and stability, 111-112
receiving, 112
storage/quarantine area, 113
sealing, 154-155
water: the essential raw material, 106-110
definition, 106
distillation, 108-110
pretreatment, 106-107
reverse osmosis, 107-108
Liposome and lipid SVP products, 2
preparation of, 69-70, 71, 72
Lyophilization (see Freeze drying)
Maintenance procedures for sterile areas in SVP manufacturing facilities, 16-17, 18
Maltose, collapse temperature of, 174
Management role in the cleanroom operation, 404-409
Manufacturing large and small volume parenterals [see Large volume parenterals (LVPs), manufacture of; Small
volume parenterals (SVPs), manufacture of products]
Master file, 5
Material logs, 5, 6-7

page_587
Mechanical services, design concepts for, 264-274
distribution system, 266-267
joining techniques, 270
materials, 268-269
surface finish, 269-270
utility service connection arrangement, 273-274
valving, 270-273
Membrane filters, 129-130
advantages of, 134-135
Methylcellulose, collapse temperature of, 174
Methylparaben, 559
Microbial resistance, principles of, 481-482
Miotics, 550
Moist heat as a sterilizing agent, 487-490
loading considerations for, 504-506
Monosodium glutamate, collapse temperature of, 174
Mydriatics, 549-550
Ointments, 577
Ophthalmic formulations, 541-581
anatomy of the eye, 542-547
ciliary body, 546
conjunctiva, 542
cornea; 544-546
crystalline lens, 546-547
lacrimal system, 542-544
optic nerve and optic disc, 547
vitreous chamber, 547

page_587
development of, 546-571
absorption of drugs from the eye, 551-555
examples of formulation development, 569-571
formulation development, 555-569
pharmacological/therapeutic categories of ophthalmic products, 548-551
gels, 576
historical background, 541-542
intraocular irrigating solution, 577-578
ointments, 577
preparation of aqueous solution for SVP products, 64-66
preparation of sterile ophthalmic


page_588

Page 588
[Ophthalmic formulations]
suspension products, 66
solutions, 571-574
active drug substance, 571
antioxidants, 573
buffers, 572
chelating agents, 573
manufacturing process, 574
osmolarity-adjusting agents, 572
preservatives, 571-572
viscosity-increasing agent, 573
Osmolarity-adjusting agents, 560-561, 572
Ovalbumin, collapse temperature of, 174
Packaging, 479
[see also Small volume parenterals (SVPs), packaging and sealing]
preparation of packaging components for SVPs, 22-34
glass components, 29-33
plastic containers, 33-34
rubber components, 22-29
selecting suitable material for, 503-504
Parasympathomimetics, 549
Peracetic acid for sterilization, 499-500
Personnel in the cleanroom operations, 367-410
application of barrier technology to the cleanroom operation, 389-391
contamination, 368-370, 451-452

page_588
management role in cleanroom operations, 404-409
personnel characteristics, 370-374
bacterial load, 370-371
body area shedding organisms, 371-372
the carrier concept, 374
male vs. female shed rates, 373
types of microorganisms, 371
personnel factors required to control contamination, 376-386
personnel practices and procedures, 386-389
general cleanroom procedures, 387-388
practices related to gowning, 386-387
safety procedures, 388-389
selection of cleanroom personnel, 374-376
characteristics of employees, 374-376
training program for cleanroom employees, 391-404
Pharmaceutical SVP products, 1
Phenylethyl alcohol, 559
Piping systems, design concepts for, 268-269
carbon steel, 268
copper, 268-269
Type 304 stainless steel, 269
Type 316 stainless steel, 269

page_588
Polyquat (polyquaternium-l), 559
Polyvinylpyrrolidone, collapse temperature of, 174
Primary freeze drying process, 165, 185-205
behavior of gases at low pressure, 187-191
heat transfer in primary drying, 191-201
mass transfer in primary drying, 201-205
sublimation of ice, 185-187
transfer operations in primary drying, 187
Process logs, 5, 6
Propylparaben, 559
Protein formulation, freeze-dried, development of (case study), 227-230
Pyrogens, 482
Q10 value, 478
Radiation for sterilization and preservation, 491-495
Radiopharmaceutical SVP products, 2
Returned goods record, 5, 7
Reverse osmosis (RO), 107-108
Ribose, collapse temperature of, 174
Sanitation, design concepts for, 313-314
Screen filters, 122
advantages and disadvantages of, 126-127
Secondary freeze drying process, 165, 205-208
role of residual water in stability of freezedried products, 207-208

page_588
Site selection for a parenteral production facility, 236-239
air quality, 238
basic plant requirements, 236-237
energy, 237-238
nontechnical factors, 239
waste disposal, 238-239
water, 238
Small volume parenterals (SVPs), 1-92
categories of, 1-2
inspection of the final product, 87
labeling, 87-89
manufacture of the product, 34-70


page_589
< pr e viou s pa ge page_589

Page 589
[Small volume parenterals (SVPs)]
preparation of aqueous ophthalmic solution products, 64-66
preparation of genetically engineered or biotechnology products, 66-69
preparation of liposome and lipid products, 69-70, 71, 72
preparation of sterile ophthalmic suspension products, 66
preparation of an SVP solution, 34-42, 43
preparation of typical freeze-dried powder formula, 51-61
preparation of typical sterile dry fill powder for constitution, 61-64
preparation of typical suspension formula, 42-51, 55
overview of, 2, 3
packaging and sealing, 70-87
aseptic packaging via form/fill/seal technology, 86-87, 88-89
aseptic subdivision, 77-80
filling equipment, 73-77
inert gas treatment, 70-73
prefilled syringes, 82-86
sealing, 80-82
preliminary stages in the processing of, 2-34
documentation control, 4-7
equipment and facilities management, 7-8
materials management, 4
personnel management, 4
planning and scheduling, 2-3
preparation of equipment, 11-22
preparation of facilities, 9-11
preparation of packaging equipment, 22-34
Sorbitol, collapse temperature of, 174

page_589
Stability records, 5, 6
Stainless steel piping, 269
Standard operating procedures, 5
Sterile ophthalmic suspension products, 66
Sterility, definition of, 473-474
Sterilization (see also Industrial sterilization) sterilization assurance, definition of, 482-486
Sucrose, collapse temperature of, 174
Surface tension (of fluids), 99-100
Surfactants, 561
Suspensions, 574-576
suspension formula for SVPs, 42-51, 55
Sympathomimetics, 549
Test methods used for effective environmental control, 454-469
airborne microbial sampling in critically controlled environments, 467-468
airborne particle count test, 459-462
airflow patterns test, 463-465
airflow uniformity test, 454-455
enclosure induction leak test, 462-463
HEPA filter leak test, 458-459
humidity control test, 456
particle dispersion test, 465-466
pressurization control test, 457
recovery test, 467
surface sampling, 468-469
temperature control test, 456
Thermal chemical death time (TCDT), 480-481
Thermal death time (TDT), 480-481
Thermal resistance, 103-106

page_589
Thimerosal, 558
Toxoids, 68-69
Training program for cleanroom employees, 391-404
classroom/orientation training, 394-399
documentation, 400
evaluation, 400-403
on-the-job training, 399-400
technical training, 399
Trehalose, collapse temperature of, 174
Type 304 stainless steel piping, 269
Type 316 stainless steel piping, 269
Validation records, 5-6
Vapor pressure, 100-101
Viral vaccines, 68
Viscoelastic agents, 550, 564-567
Viscosity, 95-98
Viscosity-increasing agents, 561, 573
Warehousing, design concepts for, 263-264
Waste disposal, design concepts for, 312-313
Water, 238
phase diagram for, 166
treatment for (design concepts), 302-304
Water for injection (WFI), 106-110, 304-312
control components, 311-312

page_589
definition, 106
distillation, 108-110, 306
distribution, 309-311
pretreatment, 106-107
reverse osmosis, 107-108
storage, 306-309
Z value, 476-478
< pr e viou s pa ge page_589

Lachman Vol2 Parenteral PDF

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Lachman Vol2 Parenteral PDF

Uploaded by

Copyright:

Available Formats

cover

Start of Citation[PU]Marcel Dekker, Inc.[/PU][DP]1992[/DP]End of Citation

title : Pharmaceutical Dosage Forms. Vol. 2: Parenteral Medications

< pr e viou s pa ge page_i n e x t pa ge >

Pharmaceutical Dosage Forms:

Second Edition, Revised and Expanded

Start of Citation[PU]Marcel Dekker, Inc.[/PU][DP]1992[/DP]End of Citation

< pr e viou s pa ge page_i n e x t pa ge >

< pr e viou s pa ge page_ii n e x t pa ge >

Library of Congress CataloginginPublication Data

Pharmaceutical dosage forms, parenteral medications / edited by

This book is printed on acid-free paper.

Copyright © 1992 by MARCEL DEKKER, INC. All Rights Reserved

MARCEL DEKKER, INC.

Current printing (last digit):

PRINTED IN THE UNITED STATES OF AMERICA

< pr e viou s pa ge page_ii n e x t pa ge >

< pr e viou s pa ge page_iii n e x t pa ge >

< pr e viou s pa ge page_iii n e x t pa ge >

< pr e viou s pa ge page_iv n e x t pa ge >

< pr e viou s pa ge page_iv n e x t pa ge >

< pr e viou s pa ge page_v n e x t pa ge >

< pr e viou s pa ge page_v n e x t pa ge >

< pr e viou s pa ge page_vi n e x t pa ge >

< pr e viou s pa ge page_vi n e x t pa ge >

< pr e viou s pa ge page_vii n e x t pa ge >

Contents of Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1 and 3 xi

Contents of Pharmaceutical Dosage Forms: Tablets, Volumes 1-3 xiii

Contents of Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1 and 2 xv

1. The Processing of Small Volume Parenterals and Related Sterile Products 1

2. Factors Involved in Manufacturing Large Volume Parenterals 93

3. Freeze Drying: Principles and Practice 163

4. Design Considerations for a Parenteral Production Facility 235

5. Biopharmaceutical Manufacturing Facility Design 317

6. Personnel: The Key Factor in Clean Room Operations 367

7. Environmental Control in Parenteral Drug 411

Start of Citation[PU]Marcel Dekker, Inc.[/PU][DP]1992[/DP]End of Citation

< pr e viou s pa ge page_vii n e x t pa ge >

< pr e viou s pa ge page_viii n e x t pa ge >

8. Industrial Sterilization: A Review of Current Principles and Practices 473

9. Development of Ophthalmic Formulations 541

Start of Citation[PU]Marcel Dekker, Inc.[/PU][DP]1992[/DP]End of Citation

< pr e viou s pa ge page_viii n e x t pa ge >

< pr e viou s pa ge page_ix n e x t pa ge >

Gary L. Hoffman Merck Pharmaceutical Manufacturing Division, West Point, Pennsylvania

Nicholas J. Kartinos, Ph.D. Consultant, Chicago, Illinois

< pr e viou s pa ge page_ix n e x t pa ge >

< pr e viou s pa ge page_x n e x t pa ge >

Karen L. Malik Baxter Healthcare Laboratories, Inc., Round Lake, Illinois

< pr e viou s pa ge page_x n e x t pa ge >

< pr e viou s pa ge page_xi n e x t pa ge >

Contents of Pharmaceutical Dosage Forms:

3. Biopharmaceutics of Injectable Medications, Sol Motola

4. Preformulation Research of Parenteral Medications, Sol Motola and Shreeram N. Agharkar

5. Formulation of Small Volume Parenterals, Patrick P. DeLuca and James C. Boylan

6. Formulation of Large Volume Parenterals, Levit J. Demorest and Jeffrey G. Hamilton

7. Parenteral Products of Peptides and Proteins, Yu-Chang John Wang

8. Sterile Diagnostics, Leif E. Olsen

9. Glass Containers for Parenterals, R. Paul Abendroth and Robert N. Clark

< pr e viou s pa ge page_xi n e x t pa ge >

< pr e viou s pa ge page_xii n e x t pa ge >

2. Records and Reports

4. Validation of Sterilization Processes and Sterile Products

5. Federal Regulation of Parenterals